GlassScriptPhysician profile
Michael R Fredericks
NPI 1699730341
$7,031.66
in general payments reported to CMS, 2019-2025
33 companies · $1,384 in 2025
The $1,384 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $201 · 2021: $1,142 · 2022: $1,027 · 2023: $927 · 2024: $1,734 · 2025: $1,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,554 · Education: $267 · Consulting Fee: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,553.79 |
| Education | $267.12 |
| Consulting Fee | $225.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $752.31 | 2019-2025 | Farxiga, Lokelma |
| Ardelyx, INC. | $736.68 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Travere Therapeutics, INC. | $722.04 | 2022-2025 | Filspari |
| Vifor Pharma, INC. | $673.88 | 2019-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $530.15 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $436.25 | 2019-2025 | Velphoro |
| Mallinckrodt Hospital Products INC. | $396.11 | 2021-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $356.87 | 2022-2025 | Jynarque, Voyxact |
| Sanofi US Services INC. | $350.00 | 2021 | |
| Daiichi Sankyo INC. | $321.26 | 2019-2022 | |
| Akebia Therapeutics INC | $268.50 | 2019-2024 | Auryxia, Vafseo |
| Opko Pharmaceuticals, LLC | $243.06 | 2019-2025 | Rayaldee |
| Novo Nordisk INC | $210.75 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $183.61 | 2019-2023 | Parsabiv, Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.15 | 2023-2025 | Jardiance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $97.44 | 2021-2023 | Benlysta |
| Accord Healthcare, INC. | $74.81 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $66.19 | 2021-2023 | Lupkynis |
| Calliditas Therapeutics US INC. | $62.71 | 2022-2025 | Tarpeyo |
| Sumitomo Pharma America, INC. | $58.18 | 2023-2024 | Gemtesa |
| Horizon Therapeutics Plc | $55.54 | 2022-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $53.97 | 2023-2024 | |
| Welch Allyn | $34.73 | 2021 | |
| Scpharmaceuticals INC. | $33.23 | 2025 | |
| Baxter Healthcare | $32.56 | 2022 | |
| Ani Pharmaceuticals, INC. | $30.32 | 2025 | Purified Cortrophin Gel |
| 180 Medical, INC. | $27.69 | 2019 | |
| Nxstage Medical, INC. | $27.51 | 2021 | |
| Genentech USA, INC. | $19.87 | 2025 | Gazyva |
| Tolmar Pharmaceuticals, INC. | $18.33 | 2021 | |
| Abbvie INC. | $17.54 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $13.42 | 2023 | Inpefa |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fredericks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.